{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:32:40Z","timestamp":1792553560367,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41585-024-00901-y","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T22:02:10Z","timestamp":1719871330000},"page":"55-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CRISPR\u2013Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-5470","authenticated-orcid":false,"given":"Danielle J.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Lunj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-0013","authenticated-orcid":false,"given":"Antony D.","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-6223","authenticated-orcid":false,"given":"Sankari","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-630X","authenticated-orcid":false,"given":"Tim A. D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley J.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-9567","authenticated-orcid":false,"given":"Peter J.","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"901_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj, T., Gersbach, C. A. & Barbas, C. F. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397\u2013405 (2013).","journal-title":"Trends Biotechnol."},{"key":"901_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/jmedgenet-2014-102968","volume":"52","author":"L Xiao-Jie","year":"2015","unstructured":"Xiao-Jie, L., Hui-Ying, X., Zun-Ping, K., Jin-Lian, C. & Li-Juan, J. CRISPR-Cas9: A new and promising player in gene therapy. J. Med. Genet. 52, 289\u2013296 (2015).","journal-title":"J. Med. Genet."},{"key":"901_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41580-022-00571-x","volume":"24","author":"SW Awwad","year":"2023","unstructured":"Awwad, S. W., Serrano-Benitez, A., Thomas, J. C., Gupta, V. & Jackson, S. P. Revolutionizing DNA repair research and cancer therapy with CRISPR\u2013Cas screens. Nat. Rev. Mol. Cell Biol. 24, 477\u2013494 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"901_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s11658-023-00483-4","volume":"28","author":"M Wang","year":"2023","unstructured":"Wang, M., Chen, M., Wu, X., Huang, X. & Yu, B. CRISPR applications in cancer diagnosis and treatment. Cell. Mol. Biol. Lett. 28, 73 (2023).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"901_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12943-022-01552-6","volume":"21","author":"S Das","year":"2022","unstructured":"Das, S., Bano, S., Kapse, P. & Kundu, G. C. CRISPR based therapeutics: a new paradigm in cancer precision medicine. Molecular Cancer 21, 85 (2022).","journal-title":"Molecular Cancer"},{"key":"901_CR6","unstructured":"Cancer Research UK. Bladder cancer incidence statistics. CRUK www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bladder-cancer\/incidence (2022)."},{"key":"901_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline. J. Urol. 196, 1021\u20131029 (2016).","journal-title":"J. Urol."},{"key":"901_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","volume":"76","author":"R Nadal","year":"2019","unstructured":"Nadal, R. & Bellmunt, J. Management of metastatic bladder cancer. Cancer Treat. Rev. 76, 10\u201321 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"901_CR9","first-page":"4","volume":"8","author":"J Perera","year":"2022","unstructured":"Perera, J. & Hoskin, P. The role of radiotherapy in metastatic bladder cancer. J. Cancer Metastasis Treat. 8, 4 (2022).","journal-title":"J. Cancer Metastasis Treat."},{"key":"901_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","volume":"110","author":"YP Song","year":"2021","unstructured":"Song, Y. P. et al. Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON (Bladder Carbogen Nicotinamide) phase 3 randomized trial (ISRCTN45938399). Int. J. Radiat. Oncol. Biol. Phys. 110, 1407\u20131415 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"901_CR11","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.2147\/OTT.S135157","volume":"11","author":"DD Stenehjem","year":"2018","unstructured":"Stenehjem, D. D., Tran, D., Nkrumah, M. A. & Gupta, S. PD1\/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther. 11, 5973\u20135989 (2018).","journal-title":"Onco Targets Ther."},{"key":"901_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","volume":"13","author":"A Lopez-Beltran","year":"2021","unstructured":"Lopez-Beltran, A. et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers 13, 131 (2021).","journal-title":"Cancers"},{"key":"901_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ctrv.2017.12.007","volume":"64","author":"F Massari","year":"2018","unstructured":"Massari, F. et al. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat. Rev. 64, 11\u201320 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"901_CR14","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.21037\/tau-2019-mibc-12","volume":"9","author":"MHY Fong","year":"2020","unstructured":"Fong, M. H. Y., Feng, M., McConkey, D. J. & Choi, W. Update on bladder cancer molecular subtypes. Transl Androl. Urol. 9, 2881 (2020).","journal-title":"Transl Androl. Urol."},{"key":"901_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-018-0727-5","volume":"20","author":"DJ McConkey","year":"2018","unstructured":"McConkey, D. J. & Choi, W. Molecular subtypes of bladder cancer. Curr. Oncol. Rep. 20, 1\u20137 (2018).","journal-title":"Curr. Oncol. Rep."},{"key":"901_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"901_CR17","unstructured":"Marraffini, L. A. in Streptococcus pyogenes: Basic Biology to Clinical Manifestations (eds Ferretti, J. J., Stevens, D. L. & Fischetti V. A.) (Univ. Oklahoma Health Scinces Center, 2016)."},{"key":"901_CR18","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096, (2014).","journal-title":"Science"},{"key":"901_CR19","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262\u20131278 (2014).","journal-title":"Cell"},{"key":"901_CR20","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.3390\/ijms24086894","volume":"24","author":"N Gunitseva","year":"2023","unstructured":"Gunitseva, N., Evteeva, M., Borisova, A., Patrushev, M. & Subach, F. RNA-dependent RNA targeting by CRISPR-Cas systems: characterizations and applications. Int. J. Mol. Sci. 24, 6894 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"901_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","volume":"20","author":"A Pickar-Oliver","year":"2019","unstructured":"Pickar-Oliver, A. & Gersbach, C. A. The next generation of CRISPR\u2013Cas technologies and applications. Nat. Rev. Mol. Cell Biol. 20, 490\u2013507 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"901_CR22","doi-asserted-by":"publisher","first-page":"639648","DOI":"10.1016\/j.dnarep.2004.12.005","volume":"4","author":"ML Hefferin","year":"2005","unstructured":"Hefferin, M. L. & Tomkinson, A. E. Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair 4, 639648 (2005).","journal-title":"DNA Repair"},{"key":"901_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nbt.3198","volume":"33","author":"VT Chu","year":"2015","unstructured":"Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33, 543\u2013548 (2015).","journal-title":"Nat. Biotechnol."},{"key":"901_CR24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","volume":"20","author":"R Scully","year":"2019","unstructured":"Scully, R., Panday, A., Elango, R. & Willis, N. A. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat. Rev. Mol. Cell Biol. 20, 698\u2013714 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"901_CR25","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1101\/gr.275607.121","volume":"31","author":"TI Jensen","year":"2021","unstructured":"Jensen, T. I. et al. Targeted regulation of transcription in primary cells using CRISPRa and CRISPRi. Genome Res. 31, 2120\u20132130 (2021).","journal-title":"Genome Res."},{"key":"901_CR26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nmeth.2598","volume":"10","author":"ML Maeder","year":"2013","unstructured":"Maeder, M. L. et al. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods 10, 977\u2013979 (2013).","journal-title":"Nat. Methods"},{"key":"901_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1089\/crispr.2020.0064","volume":"3","author":"J Armando Casas-Mollano","year":"2020","unstructured":"Armando Casas-Mollano, J., Zinselmeier, M. H., Erickson, S. E. & Smanski, M. J. CRISPR-Cas activators for engineering gene expression in higher eukaryotes. CRISPR J. 3, 350\u2013364 (2020).","journal-title":"CRISPR J."},{"key":"901_CR28","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1038\/nprot.2013.132","volume":"8","author":"MH Larson","year":"2013","unstructured":"Larson, M. H. et al. CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat. Protoc. 8, 2180\u20132196 (2013).","journal-title":"Nat. Protoc."},{"key":"901_CR29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"LA Gilbert","year":"2013","unstructured":"Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 422\u2013451 (2013).","journal-title":"Cell"},{"key":"901_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"901_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of T to G C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"901_CR32","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1042\/BCJ20170793","volume":"475","author":"A Eid","year":"2018","unstructured":"Eid, A., Alshareef, S. & Mahfouz, M. M. CRISPR base editors: Genome editing without double-stranded breaks. Biochem. J. 475, 1955\u20131964 (2018).","journal-title":"Biochem. J."},{"key":"901_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"901_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","volume":"40","author":"JW Nelson","year":"2022","unstructured":"Nelson, J. W. et al. Engineered pegRNAs improve prime editing efficiency. Nat. Biotechnol. 40, 402\u2013410 (2022).","journal-title":"Nat. Biotechnol."},{"key":"901_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"901_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.1246981","volume":"343","author":"T Wang","year":"2014","unstructured":"Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80\u201384 (2014).","journal-title":"Science"},{"key":"901_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 1\u201312 (2014).","journal-title":"Genome Biol."},{"key":"901_CR38","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","volume":"163","author":"B Zetsche","year":"2015","unstructured":"Zetsche, B. et al. Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. Cell 163, 759\u2013771 (2015).","journal-title":"Cell"},{"key":"901_CR39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.cell.2018.09.001","volume":"175","author":"C Zhang","year":"2018","unstructured":"Zhang, C. et al. Structural Basis for the RNA-Guided Ribonuclease Activity of CRISPR-Cas13d. Cell 175, 212\u2013223 (2018).","journal-title":"Cell"},{"key":"901_CR40","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nmeth.4042","volume":"13","author":"Y Gao","year":"2016","unstructured":"Gao, Y. et al. Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. Nat. Methods 13, 1043\u20131049 (2016).","journal-title":"Nat. Methods"},{"key":"901_CR41","doi-asserted-by":"publisher","first-page":"eaaw6499","DOI":"10.1126\/sciadv.aaw6499","volume":"5","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Delivery of RIPK4 small interfering RNA for bladder cancer therapy using natural halloysite nanotubes. Sci. Adv. 5, eaaw6499 (2019).","journal-title":"Sci. Adv."},{"key":"901_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-2362.2010.02400.x","volume":"41","author":"SH Chen","year":"2011","unstructured":"Chen, S. H. & Zhaori, G. Potential clinical applications of siRNA technique: Benefits and limitations. Eur. J. Clin. Invest. 41, 221\u2013232 (2011).","journal-title":"Eur. J. Clin. Invest."},{"key":"901_CR43","doi-asserted-by":"publisher","first-page":"9529","DOI":"10.1007\/s11033-023-08749-y","volume":"50","author":"H Isazadeh","year":"2023","unstructured":"Isazadeh, H. et al. Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities. Mol. Biol. Rep. 50, 9529\u20139543 (2023).","journal-title":"Mol. Biol. Rep."},{"key":"901_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.critrevonc.2015.05.005","volume":"96","author":"F Massari","year":"2015","unstructured":"Massari, F. et al. Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Crit. Rev. Oncol. Hematol. 96, 81\u201390 (2015).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"901_CR45","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869\u20131883 (2012).","journal-title":"Oncogene"},{"key":"901_CR46","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.fct.2012.01.040","volume":"50","author":"HM Yu","year":"2012","unstructured":"Yu, H. M. & Wang, T. C. Mechanism of cisplatin resistance in human urothelial carcinoma cells. Food Chem. Toxicol. 50, 1226\u20131237 (2012).","journal-title":"Food Chem. Toxicol."},{"key":"901_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jare.2021.11.010","volume":"39","author":"S Liu","year":"2022","unstructured":"Liu, S., Chen, X. & Lin, T. Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives. J. Adv. Res. 39, 187\u2013202 (2022).","journal-title":"J. Adv. Res."},{"key":"901_CR48","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.urolonc.2020.10.050","volume":"38","author":"G Kumar","year":"2020","unstructured":"Kumar, G. et al. Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of cisplatin sensitivity in muscle-invasive bladder cancer. Urol. Oncol. Semin. Ori. 38, 905 (2020).","journal-title":"Urol. Oncol. Semin. Ori."},{"key":"901_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/1061186X.2019.1616746","volume":"28","author":"J Luan","year":"2020","unstructured":"Luan, J., Gao, X., Hu, F., Zhang, Y. & Gou, X. SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents). J. Drug Target. 28, 33\u201340 (2020).","journal-title":"J. Drug Target."},{"key":"901_CR50","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41416-021-01476-w","volume":"125","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. Br. J. Cancer 125, 1333\u20131340 (2021).","journal-title":"Br. J. Cancer"},{"key":"901_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01360-4","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutS\u03b1\/ATM-p73 axis in bladder cancer. Mol. Cancer 20, 1\u201320 (2021).","journal-title":"Mol. Cancer"},{"key":"901_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12943-022-01517-9","volume":"21","author":"ZD Shi","year":"2022","unstructured":"Shi, Z.D. et al. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer. Mol. Cancer 21, 37 (2022).","journal-title":"Mol. Cancer"},{"key":"901_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.dnarep.2003.10.005","volume":"3","author":"L Lan","year":"2004","unstructured":"Lan, L. et al. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells. DNA Repair 3, 135\u2013143 (2004).","journal-title":"DNA Repair"},{"key":"901_CR54","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/bjc.1997.372","volume":"76","author":"PJ Hoskin","year":"1997","unstructured":"Hoskin, P. J. et al. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br. J. Cancer 76, 260\u2013263 (1997).","journal-title":"Br. J. Cancer"},{"key":"901_CR55","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","volume":"28","author":"PJ Hoskin","year":"2010","unstructured":"Hoskin, P. J., Rojas, A. M., Bentzen, S. M. & Saunders, M. I. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J. Clin. Oncol. 28, 4912\u20134918 (2010).","journal-title":"J. Clin. Oncol"},{"key":"901_CR56","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.1016\/j.ctarc.2020.100296","volume":"26","author":"LP Rhea","year":"2021","unstructured":"Rhea, L. P., Mendez-Marti, S., Kim, D. & Aragon-Ching, J. B. Role of immunotherapy in bladder cancer. Cancer Treat. Res. Commun. 26, 100296 (2021).","journal-title":"Cancer Treat. Res. Commun."},{"key":"901_CR57","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. 29, 2825\u20132834 (2023).","journal-title":"Nat. Med."},{"key":"901_CR58","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00280-019-03800-x","volume":"83","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. Disruption of CTLA-4 expression on peripheral blood CD8\u2009+\u2009T cell enhances anti-tumor efficacy in bladder cancer. Cancer Chemother. Pharmacol. 83, 911\u2013920 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"901_CR59","doi-asserted-by":"publisher","first-page":"9634","DOI":"10.18632\/oncotarget.14176","volume":"8","author":"S Zhen","year":"2017","unstructured":"Zhen, S. et al. Inhibition of long non-coding RNA UCA1 by CRISPR\/Cas9 attenuated malignant phenotypes of bladder cancer. Oncotarget 8, 9634 (2017).","journal-title":"Oncotarget"},{"key":"901_CR60","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1089\/hum.2018.048","volume":"29","author":"S Zhen","year":"2018","unstructured":"Zhen, S., Lu, J., Chen, W., Zhao, L. & Li, X. Synergistic antitumor effect on bladder cancer by rational combination of programmed cell death 1 blockade and CRISPR-Cas9-mediated long non-coding RNA urothelial carcinoma associated 1 knockout. Hum. Gene Ther. 29, 1352\u20131363 (2018).","journal-title":"Hum. Gene Ther."},{"key":"901_CR61","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.canlet.2020.11.048","volume":"501","author":"A Nandwani","year":"2021","unstructured":"Nandwani, A., Rathore, S. & Datta, M. LncRNAs in cancer: Regulatory and therapeutic implications. Cancer Lett. 501, 162\u2013171 (2021).","journal-title":"Cancer Lett."},{"key":"901_CR62","doi-asserted-by":"publisher","first-page":"112861","DOI":"10.1016\/j.ejmech.2020.112861","volume":"209","author":"ZX He","year":"2021","unstructured":"He, Z. X. et al. Current development of CBP\/p300 inhibitors in the last decade. Eur. J. Med. Chem. 209, 112861 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"901_CR63","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1038\/ncomms6393","volume":"5","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Synthesizing and gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nat. Commun. 5, 5393 (2014).","journal-title":"Nat. Commun."},{"key":"901_CR64","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.7150\/ijbs.32332","volume":"15","author":"J Li","year":"2019","unstructured":"Li, J. et al. A CRISPR interference of CBP and p300 selectively induced synthetic lethality in bladder cancer cells in vitro. Int. J. Biol. Sci. 15, 1276 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"901_CR65","first-page":"1913","volume":"11","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. CDK inhibitors in cancer therapy, an overview of recent development. Am. J. Cancer Res. 11, 1913 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"901_CR66","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41416-018-0229-0","volume":"119","author":"TL Rose","year":"2018","unstructured":"Rose, T. L. et al. Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. Br. J. Cancer 119, 801\u2013807 (2018).","journal-title":"Br. J. Cancer"},{"key":"901_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1322-9","volume":"38","author":"Z Tong","year":"2019","unstructured":"Tong, Z. et al. Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4\/6 inhibition in bladder cancer. J. Exp. Clin. Cancer Res. 38, 1\u201314 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"901_CR68","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41420-023-01416-y","volume":"9","author":"Z He","year":"2023","unstructured":"He, Z., He, J. & Xie, K. KLF4 transcription factor in tumorigenesis. Cell Death Discov. 9, 118 (2023).","journal-title":"Cell Death Discov."},{"key":"901_CR69","doi-asserted-by":"publisher","first-page":"10278","DOI":"10.18632\/oncotarget.22158","volume":"8","author":"X Xu","year":"2017","unstructured":"Xu, X. et al. CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer in vitro and in vivo. Oncotarget 8, 10278 (2017).","journal-title":"Oncotarget"},{"key":"901_CR70","doi-asserted-by":"publisher","first-page":"106409","DOI":"10.1016\/j.bioorg.2023.106409","volume":"133","author":"LJ Chen","year":"2023","unstructured":"Chen, L. J. et al. The role of lysine-specific demethylase 6\u2009A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy. Bioorg. Chem. 133, 106409 (2023).","journal-title":"Bioorg. Chem."},{"key":"901_CR71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2217\/pgs-2023-0027","volume":"24","author":"M Matar","year":"2023","unstructured":"Matar, M. et al. Implication of KDM6A in bladder cancer. Pharmacogenomics 24, 509\u2013522 (2023).","journal-title":"Pharmacogenomics"},{"key":"901_CR72","doi-asserted-by":"publisher","first-page":"63252","DOI":"10.18632\/oncotarget.11207","volume":"7","author":"J Ahn","year":"2016","unstructured":"Ahn, J. et al. Target sequencing and CRISPR\/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer. Oncotarget 7, 63252 (2016).","journal-title":"Oncotarget"},{"key":"901_CR73","doi-asserted-by":"publisher","first-page":"eaai8312","DOI":"10.1126\/scitranslmed.aai8312","volume":"9","author":"LD Ler","year":"2017","unstructured":"Ler, L. D. et al. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci. Transl Med. 9, eaai8312 (2017).","journal-title":"Sci. Transl Med."},{"key":"901_CR74","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3390\/cancers11040481","volume":"11","author":"A Lang","year":"2019","unstructured":"Lang, A. et al. Contingencies of UTX\/KDM6A action in urothelial carcinoma. Cancers 11, 481 (2019).","journal-title":"Cancers"},{"key":"901_CR75","doi-asserted-by":"publisher","first-page":"646412","DOI":"10.3389\/fmolb.2021.646412","volume":"8","author":"C Zhuang","year":"2021","unstructured":"Zhuang, C. et al. Engineered CRISPR\/Cas13d Sensing hTERT Selectively Inhibits the Progression of Bladder Cancer In Vitro. Front. Mol. Biosci. 8, 646412 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"901_CR76","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","volume":"65","author":"VE Hillary","year":"2023","unstructured":"Hillary, V. E. & Ceasar, S. A. A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering. Mol. Biotechnol. 65, 311\u2013325 (2023).","journal-title":"Mol. Biotechnol."},{"key":"901_CR77","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3892\/ol.2016.4770","volume":"12","author":"R Zhang","year":"2016","unstructured":"Zhang, R., Xia, L. Q., Lu, W. W., Zhang, J. & Zhu, J. S. LncRNAs and cancer. Oncol. Lett. 12, 1233\u20131239 (2016).","journal-title":"Oncol. Lett."},{"key":"901_CR78","doi-asserted-by":"publisher","first-page":"5718","DOI":"10.1002\/cam4.5316","volume":"12","author":"J Xie","year":"2023","unstructured":"Xie, J. et al. LncRNA SNHG3 enhances BMI1 mRNA stability by binding and regulating c-MYC: Implications for the carcinogenic role of SNHG3 in bladder cancer. Cancer Med. 12, 5718\u20135735 (2023).","journal-title":"Cancer Med."},{"key":"901_CR79","doi-asserted-by":"publisher","first-page":"106525","DOI":"10.1016\/j.isci.2023.106525","volume":"26","author":"D Tortora","year":"2023","unstructured":"Tortora, D. et al. A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer. iScience 26, 106525 (2023).","journal-title":"iScience"},{"issue":"Suppl. 1","key":"901_CR80","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2020-139575","volume":"136","author":"H Frangoul","year":"2020","unstructured":"Frangoul, H. et al. Safety and efficacy of CTX001 in patients with transfusion-dependent \u03b2-thalassemia and sickle cell disease: early results from the Climb THAL-111 and Climb SCD-121 studies of autologous CRISPR-CAS9-modified CD34+\u2009hematopoietic stem and progenitor cells. Blood 136 (Suppl. 1), 3\u20134 (2020).","journal-title":"Blood"},{"key":"901_CR81","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","volume":"27","author":"Y Hu","year":"2021","unstructured":"Hu, Y. et al. CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 27, 2764\u20132772 (2021).","journal-title":"Clin. Cancer Res."},{"key":"901_CR82","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-021-01115-0","volume":"14","author":"AM Tsimberidou","year":"2021","unstructured":"Tsimberidou, A. M. et al. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J. Hematol. Oncol. 14, 102 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"901_CR83","doi-asserted-by":"publisher","first-page":"101285","DOI":"10.1016\/j.beha.2021.101285","volume":"34","author":"E Tan","year":"2021","unstructured":"Tan, E., Gakhar, N. & Kirtane, K. TCR gene-engineered cell therapy for solid tumors. Best Prac. Res. Clin. Haematol. 34, 101285 (2021).","journal-title":"Best Prac. Res. Clin. Haematol."},{"key":"901_CR84","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","volume":"32","author":"J He","year":"2022","unstructured":"He, J. et al. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Res. 32, 530\u2013542 (2022).","journal-title":"Cell Res."},{"key":"901_CR85","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy, S. P. et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature 615, 687\u2013696 (2023).","journal-title":"Nature"},{"key":"901_CR86","doi-asserted-by":"publisher","first-page":"2033528","DOI":"10.1080\/2162402X.2022.2033528","volume":"11","author":"TLA Wachsmann","year":"2022","unstructured":"Wachsmann, T. L. A. et al. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. Oncoimmunology 11, 2033528 (2022).","journal-title":"Oncoimmunology"},{"key":"901_CR87","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41565-022-01122-3","volume":"17","author":"D Zhang","year":"2022","unstructured":"Zhang, D. et al. Enhancing CRISPR\/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat. Nanotechnol. 17, 777\u2013787 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"901_CR88","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04426669 (2023)."},{"key":"901_CR89","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05795595 (2024)."},{"key":"901_CR90","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39, 154\u2013173 (2021).","journal-title":"Cancer Cell"},{"key":"901_CR91","doi-asserted-by":"publisher","first-page":"649896","DOI":"10.3389\/fmed.2021.649896","volume":"8","author":"Y Yang","year":"2021","unstructured":"Yang, Y., Xu, J., Ge, S. & Lai, L. CRISPR\/Cas: advances, limitations, and applications for precision cancer research. Front. Med. 8, 649896 (2021).","journal-title":"Front. Med."},{"key":"901_CR92","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"SW Wang","year":"2022","unstructured":"Wang, S. W. et al. Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol. Cancer 21, 57 (2022).","journal-title":"Mol. Cancer"},{"key":"901_CR93","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","volume":"33","author":"SQ Tsai","year":"2015","unstructured":"Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187\u2013197 (2015).","journal-title":"Nat. Biotechnol."},{"key":"901_CR94","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"901_CR95","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","volume":"19","author":"A Aimo","year":"2022","unstructured":"Aimo, A. et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat. Rev. Cardiol. 19, 655\u2013667 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"901_CR96","doi-asserted-by":"crossref","unstructured":"S\u00fdkora, P. Germline Gene Therapy in the Era of Precise Genome Editing: How Far Should We Go? in The Ethics of Reproductive Genetics Philosophy and Medicine Ch. 11 (ed. Soniewicka, M.) 157-171 (Springer, 2018).","DOI":"10.1007\/978-3-319-60684-2_11"},{"key":"901_CR97","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang, F. & Doudna, J. A. CRISPR-Cas9 Structures and Mechanisms. Annu. Rev. Biophys. 46, 505\u2013529 (2017).","journal-title":"Annu. Rev. Biophys."},{"key":"901_CR98","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","volume":"431","author":"C Brokowski","year":"2019","unstructured":"Brokowski, C. & Adli, M. CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool. J. Mol. Biol. 431, 88\u2013101 (2019).","journal-title":"J. Mol. Biol."},{"key":"901_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-015-0846-3","volume":"16","author":"Y Dang","year":"2015","unstructured":"Dang, Y. et al. Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. Genome Biol. 16, 1\u201310 (2015).","journal-title":"Genome Biol."},{"key":"901_CR100","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature13011","volume":"507","author":"SH Sternberg","year":"2014","unstructured":"Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C. & Doudna, J. A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507, 62\u201367 (2014).","journal-title":"Nature"},{"key":"901_CR101","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.celrep.2017.12.041","volume":"22","author":"S Gong","year":"2018","unstructured":"Gong, S., Yu, H. H., Johnson, K. A. & Taylor, D. W. DNA unwinding is the primary determinant of CRISPR-Cas9 activity. Cell Rep. 22, 359\u2013371 (2018).","journal-title":"Cell Rep."},{"key":"901_CR102","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"901_CR103","first-page":"130","volume":"2","author":"AJ Davis","year":"2013","unstructured":"Davis, A. J. & Chen, D. J. DNA double strand break repair via non-homologous end-joining. Transl Cancer Res. 2, 130 (2013).","journal-title":"Transl Cancer Res."},{"key":"901_CR104","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1073\/pnas.95.9.5172","volume":"95","author":"F Liang","year":"1998","unstructured":"Liang, F., Han, M., Romanienko, P. J. & Jasin, M. Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc. Natl Acad. Sci. USA 95, 5172\u20135177 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"901_CR105","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"CA Lino","year":"2018","unstructured":"Lino, C. A., Harper, J. C., Carney, J. P. & Timlin, J. A. Delivering CRISPR: A review of the challenges and approaches. Drug Deliv. 25, 1234\u20131257 (2018).","journal-title":"Drug Deliv."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00901-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00901-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00901-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T14:06:49Z","timestamp":1736258809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00901-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1038\/s41585-024-00901-y","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"29 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}